How teduglutide affects intestinal organoids from children with short bowel syndrome

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study obtains intestinal tissue from pediatric SBS patients (typically at the time of resection) and grows patient-derived intestinal organoids in the laboratory. Organoids will be treated with teduglutide or left untreated to compare effects on growth, cell composition, and markers of absorption. Molecular and functional assays will be used to identify pathways and biomarkers associated with different responses. Researchers will relate organoid results to patients' clinical histories to seek predictors of who benefits from teduglutide.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients or His/her Parents/ legal guardian must provide informed consent before they can participate in the study.
* Paediatric patients: Male and female patients aged ≥ 4 months old and ≤ 18 years;
* SBS patient or patient undergoing intestinal resective surgery

Exclusion Criteria:

* Adult patients (≥ 18 years old);
* Patients who have never undergone intestinal resective surgery
* Current or past use of teduglutide

Where it's running

• Aou Meyer IRCSS
  Florence, Florence, Italy Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Apraglutide vs placebo in adults with short bowel syndrome and intestinal failure

  This Phase 3 study tests whether weekly injections of apraglutide help adults with SBS-IF who rely on parenteral nutrition, compared with placebo, over 24 weeks.

  Recruiting Phase 3 VectivBio AG · Los Angeles, California and 93 other locations · NCT07742735

• Teduglutide treatment for Chinese children and teenagers with short bowel syndrome

  This test will see if teduglutide helps Chinese children and teenagers with short bowel syndrome reduce how much intravenous nutrition they need.

  Recruiting Takeda · Guangzhou, Guangdong and 3 other locations · NCT07319832

• Autoimmune podocytopathy and anti-nephrin antibodies

  This study tests whether children and adults with nephrotic syndrome have anti-nephrin autoantibodies and whether those antibodies relate to relapses and treatment response.

  Recruiting Meyer Children's Hospital IRCCS · Rochester, Minnesota and 13 other locations · NCT07516964

• Pediatric leishmaniasis in Italy: clinical and treatment patterns

  This project will collect medical information to see how leishmaniasis presents and is treated in children under 18 in Italy.

  Recruiting Meyer Children's Hospital IRCCS · Florence, Tuscany · NCT07504757

• Infliximab level monitoring in children with inflammatory bowel disease

  This project will test whether measuring infliximab levels in saliva and leftover blood during the first infusions helps monitor and personalize treatment for children and teens (ages 3–18) with Crohn's disease or ulcerative colitis.

  Recruiting Meyer Children's Hospital IRCCS · Florence, Italy · NCT07470502

• Camptodactyly–Arthropathy–Coxa Vara–Pericarditis (CACP) syndrome patient registry and genetic review

  This registry collects clinical and genetic information to better understand CACP syndrome in children with confirmed PRG4 mutations.

  Recruiting at 3 sites Meyer Children's Hospital IRCCS · Bari and 9 other locations · NCT07468461

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.